

ForPatients

by Roche

Small Cell Lung Cancer Small Cell Lung Carcinoma

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT04028050 ML41118

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a phase IIIB, single-arm, single-country, multicenter study of the safety and efficacy of atezolizumab in combination with carboplatin plus etoposide in patients who have ES-SCLC and are chemotherapy-naive for their extensive-stage disease.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT04028050 ML41118
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
